Abaloparatide

Abaloparatide, sold as Tymlos, is a daily injectable medication that belongs to the anabolic, or bone-building, family of osteoporosis treatments. It works like a parathyroid-hormone analogue: given in intermittent daily doses, it stimulates osteoblasts to actively form new bone tissue, rather than just slowing down the cells that break bone down. This sets it apart from antiresorptive drugs like bisphosphonates or denosumab, which work by suppressing osteoclasts instead.

Because it builds new bone rather than just preserving what's there, abaloparatide tends to produce larger bone density gains than antiresorptive medications, which is why it's typically reserved for people at higher risk. It's also time-limited by design, generally used for a set course of around 12 to 24 months. The gains it produces aren't self-sustaining, so standard practice is to follow an anabolic course like this one with an antiresorptive medication to help hold on to the bone that was built.

Any decisions about starting, stopping, or switching between these medications belong to your prescriber, who can weigh your individual risk factors and history. Understanding which family a medication belongs to, anabolic or antiresorptive, is one of the most useful things you can know about it, since that determines what it can and cannot do for your bones.